Citations

Clear

3042 citation(s) found for "Kumar, S".

Seeing medicine: learning to read between the shadows
Kumar, Sonal , Abdulwadood, Isra , Noland, Shelley S.

Mayo Clinic

Academic Medicine | February 20, 2026 | Volume: 101 | Issue: 4 | Pages: 459-459

10.1093/acamed/wvaf062 | PMID 42159138 Get It

Abstract PS3-06-29: Retrieval-augmented GPT-4 improves NCCN-concordant breast cancer treatment recommendations
Yost, Connor , Aseem, A., Callas, Bradley, Monick, Sarah, Bonilla, L., Galamaga, Robert , Osborn, S., Kumar, Y., Ertz-Archambault, N., Nguyen, Ryan H.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-06-29-PS3-06-29

10.1158/1557-3265.sabcs25-ps3-06-29 Get It

Abstract Guideline-concordant breast cancer treatment selection is increasingly complex due to rapid evolution in biomarker-driven therapies. Large language models (LLMs), such as GPT-4, offer a potential tool to support clinical decision-making. However, hallucinations and deviation from evidence-based guidelines remain significant concerns. This study evaluated whether retrieval-augmented generation (RAG) using National Comprehensive Cancer Network (NCCN) guidelines improves GPT-4 performance in treatment recommendation tasks. We developed a retrieval-augmented GPT-4 agent (RAG-GPT) by indexing 2025 NCCN Breast Cancer Guidelines into a vector database using sentence embeddings. Forty clinical vignettes were created from published case reports to reflect diverse scenarios, including HER2-low, triple-negative, and BRCA-mutated disease across all stages. Two models—a baseline GPT-4 (without augmentation) and the RAG-GPT—were prompted with structured templates requesting treatment plans, rationale, clinical trial options, and citations.Outputs were independently scored by two blinded oncology-trained reviewers using the modified Generative AI Performance Score (mG-PS). The mG-PS scored outputs for 2 categories, guideline concordance (Gold standard = 1.0, Acceptable = 0.5, Non-concordant = 0.0) and hallucination errors (Severe = -1.0, Moderate = -0.5, Mild = -0.25, None = 0.0). Guideline Concordance was deemed based on NCCN guidelines and what an oncologist would due based on using the guidelines for each case. Hallucinations are a term used for falsehoods in Artificial Intelligence, like made-up facts or studies, incorrect information, improper doses, or inappropriate or wrong treatments. To ensure consistency and minimize inter-rater variability, reviewers were provided with comprehensive scoring guidelines and detailed instructions for each evaluation metric. Scores were normalized between -1.0 and 1.0 for improved evaluation of tools. Readability and rationale clarity were rated on a 5-point Likert scale. Inter-rater reliability was assessed using Cohen’s kappa. The RAG-GPT demonstrated a significantly higher mean mG-PS score (0.599 ± 0.102, 95% CI: 0.498-0.702) compared to the baseline GPT-4, which not only scored lower but had a negative mean (-0.21 ± 0.143, 95% CI: -0.353 to -0.067). For the mG-PS Cohen’s Kappa test resulted in a score of .69 with substantial aggreament. An independent sample t-test showed a difference (t(78) = 29.1, p < 0.0001). Severe hallucinations were also absent in RAG-GPT outputs (0/40) but occurred in 8/40 baseline GPT-4 outputs. The evaluation of readability and rationality also showed notable differences, with the augmented LLM scoring significantly higher (M = 4.35, SD = 0.66) compared to the naïve LLM (M = 3.05, SD = 1.06). An independent samples t-test confirmed this difference t(65.3) = 6.58, p < 0.0001, further supporting the benefit of augmented Large Language models. Cohen’s Kappa test resulted in a score of .76 for a substantial agreement for readability and rational clarity scale. Limitations include small sample size; further fine-tuning and larger real-world validation studies remain necessary. Linking GPT-4 to NCCN guidelines via retrieval-augmented generation significantly improves treatment accuracy and reduces hallucination severity in breast cancer care scenarios. While further refinement is needed, the reduced incidence of severe hallucinations, increase in guideline-concordant recommendations, and enhanced readability findings support further development and prospective validation of guideline-anchored LLMs for clinical use. Citation Format: C. Yost, A. Aseem, B. Callas, S. Monick, L. Bonilla, R. Nguyen, R. Galamaga, S. Osborn, Y. Kumar, N. Ertz-Archambault. Retrieval-augmented GPT-4 improves NCCN-concordant breast cancer treatment recommendations [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-06-29.
Abstract PS2-09-08: Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database
Chumsri, S., Deshmukh, S. Kumar, Liu, Y., Wu, S., Xiu, J., Norton, N., Gandhi, S. Shipra, Torres, E., Lustberg, M. B., Perez, E., Nassar, A., Sledge, G. W., Thompson, E., Knutson, K., Chumsri, S., Xiu, Joanne, Lustberg, Maryam , Nassar, A., Thompson, E. Aubrey , Knutson, Keith L.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-09-08-PS2-09-08

10.1158/1557-3265.sabcs25-ps2-09-08 Get It

Abstract Background: Tertiary lymphoid structures (TLS), which are organized ectopic lymphoid aggregates resembling secondary lymphoid organs, have been associated with improved outcomes across various cancer types. However, limited data exist on the prognostic relevance of TLS in HER2+ BC pts treated with trastuzumab. In our prior work, we demonstrated that the presence of functional TLS, defined by lymphoid aggregates with elevated expression of BCL6 or IL21R, correlated with improved outcomes in the NCCTG N9831 trial. In this study, we evaluated TLS-related gene and outcomes in the real-world database. Methods: 1344 HER2+ (HR-HER2+: 560; HR+HER2+: 784) BC samples were analyzed via NGS (592-gene panel, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences). Above (high) or below (low) the 50th percentile expression levels of TLS-related genes were used to calculate overall survival (OS). IL21R-high (H) and -low (L) tumors were classified by RNA expression above or below the 50th percentile. Real-world OS was derived from insurance claims and calculated from date of biopsy to last contact using Kaplan-Meier. Statistical significance was assessed using chi-square and Mann-Whitney U with multiple comparison adjustments (q < 0.05). Results: Among pts with HR-HER2+ BC, high expression of IL21R, CXCL9, CD38, and CXCL10 were associated with improved OS (Table). In contrast, among pts with HR+HER2+ BC, high expression of CXCR3, PDCD1, TBX21, CD200 and IL21R, were associated with improved OS. In both HR-HER2+ and HR+HER2+, IL21R-H groups had 1) higher infiltration of B cells (HR-HER2+: 4.4% vs 2.9%; HR+HER2+: 5.6% vs 4.2%), M1 MΦ (HR-HER2+: 3.9% vs 2.6%; HR+HER2+: 3% vs 2.1%), M2 MΦ (HR-HER2+: 4% vs 3.2%; HR+HER2+: 5.7% vs 4.4%), NK cells (HR-HER2+: 2.8% vs 2.5%; HR+HER2+: 2.7% vs 2.4%), CD8+ T cell (HR-HER2+: 0.9% vs 0%; HR+HER2+: 0.7% vs 0%), Tregs (HR-HER2+: 2.9% vs 1.4%; HR+HER2+: 2.8% vs 1.5%), all q<.05; 2) higher T cell inflamed score (HR-HER2+: 87.5 vs -95; HR+HER2+: 71 vs -86), IFNy score (HR-HER2+: -0.19 vs -0.48; HR+HER2+: -0.27 vs -0.49), all q<.05; 3) higher expression levels of MHC class I genes (HLA-A, HLA-B, HLA-C, HLA-E, FC: 1.6-2.3; all q<.05), MHC class II genes (HLA-DQA1, HLA-DOA, HLA-DPA1, HLA-DMA, FC: 2.2-3.2; all q<.05) compared to IL21R-L group. Conclusion: Consistent with our prior findings, overexpression of TLS-related genes was associated with improved outcomes in HER2+ BC in real-world data. Notably, the prognostic impact of TLS-related genes differed by hormone receptor (HR) status. Among these, IL21R emerged as the only gene significantly associated with clinical outcomes across both datasets and HR subgroups. Higher IL21R expression is associated with more B cell, M1 MΦ, CD8 T cell and NK cells. These findings underscore the potential importance of the IL21/IL21R axis in HER2+ BC and warrant further investigation to validate its role and therapeutic relevance. Citation Format: S. Chumsri, S. Deshmukh, Y. Liu, S. Wu, J. Xiu, N. Norton, S. Shipra Gandhi, E. Torres, M. Lustberg, E. Perez, A. Nassar, G. Sledge, E. Thompson, K. Knutson. Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-09-08.
Abstract PS2-08-14: Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer
Deshmukh, S. Kumar, Wu, S., Xiu, Joanne , Sledge, G. W., Trapani, D., Leone, J., Chumsri, S., Lustberg, M. B., Hong, C., Yao, S., Ernstoff, M., Paulos, C. M., Lesinski, G. B., Madabhushi, A., Badve, S., Kalinsky, K., Kalinski, P., Gandhi, Shipra , Trapani, Dario , Leone, J. P. , Chumsri, S., Lustberg, Maryam , Hong, Chi‐Chen , Takabe, Kazuaki , Opyrchal, Mateusz , Chalasani, Pavani , Paulos, Chrystal M. , Lesinski, Gregory B , Badve, Sunil , Kalinsky, K. M.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-08-14-PS2-08-14

10.1158/1557-3265.sabcs25-ps2-08-14 Get It

Abstract Background: Triple-negative breast cancer (TNBC) is an aggressive yet immunogenic subtype of breast cancer (BC) and the only one with FDA-approved immune checkpoint inhibitor (ICI) - pembrolizumab. Currently, PD-L1 (22C3) is the companion biomarker for predicting pembrolizumab benefit, but its utility is limited by spatial/temporal heterogeneity, assay variability, and modest correlation with treatment response. Chemokines such as CXCL9, CXCL10, and CCL5 recruit CD8+ T cells into the tumor microenvironment and have been associated with improved response to ICI, but their predictive value alongside PD-L1 remains unclear. Here, we examined the relationship between these chemokines, PD-L1, and pembrolizumab efficacy in TNBC. Methods: We analyzed 3662 TNBC tumors profiled by NGS (592, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences). Immune cells were estimated using WTS deconvolution (Quantiseq). PD-L1 positivity was defined as >10% CPS (PharmDx 22C3). CXCL9/CXCL10/CCL5-high (H) and -low (L) TNBC were classified by RNA expression above or below 50th percentile. Real-world median overall survival (mOS) was derived from insurance claims and calculated from start of pembrolizumab to last contact using Kaplan-Meier. Statistical significance was assessed by chi-square and Mann-Whitney U with multiple comparison adjustments (q<0.05). Results: TNBC expressed higher levels of CXCL9, CXCL10, and CCL5 (N = 3662, median TPM: 5.3, 14.8, and 15.1) compared to HER2+ (N = 1344; 4.8, 10.1, 10.6) and HR+HER2- BC (N = 6097; 2.7, 6.6, 9.4), all q<0.05. Moderate correlations were observed between PD-L1 CPS and each chemokine (r = 0.41, p<.01). PD-L1-positive tumors had better mOS (24.3 months (m) vs 18.6 m, HR 0.75, 95% CI 0.6-0.92, p=0.007) compared to PD-L1-negative TNBC post-pembrolizumab. Among PD-L1-negative tumors, those with CXCL9-H had better mOS (26.9 m vs 15.8 m for CXCL9-L, HR 0.61, 95% CI 0.45-0.82, p=0.001) post-pembrolizumab. Among PD-L1-positive tumors, CXCL10-H and CCL5-H was associated with improved mOS (CXCL10-H: 25.7 m vs. 20.7 m for CXC10-L, p = 0.03; CCL5-H: 26.7 vs. 18.5 m for CCL5-L, p = 0.03) post-pembrolizumab. PD-L1 negative CXCL9-H, PD-L1 positive CXCL10-H and PD-L1 positive CCL5-H groups showed higher infiltration of CD8+ T cell, B cells, M1/M2 macrophages, Tregs. They also exhibited higher T cell inflamed score, IFNy score and MAPK activation score vs. CXCL9-L, CXCL10-L and CCL5-L groups (Table). Conclusions: In TNBC, a chemokine signature comprising CXCL9, CXCL10 and CCL5 refines PD-L1 based prediction of pembrolizumab benefit. Specifically, high CXCL10 or CCL5 expression in PD-L1-positive tumors, and high CXCL9 expression in PD-L1-negative tumors, were associated with improved survival post pembrolizumab and immune-rich microenvironment. These findings support the use of chemokine profiling to complement PD-L1 and enhance patient selection for ICI therapy in TNBC. Citation Format: S. Gandhi, S. Deshmukh, S. Wu, J. Xiu, G. Sledge Jr., D. Trapani, J. Leone, S. Chumsri, M. Lustberg, C. Hong, S. Yao, K. Takabe, M. Ernstoff, M. Opyrchal, P. Chalasani, C. Paulos, G. Lesinski, A. Madabhushi, S. Badve, K. Kalinsky, P. Kalinski. Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-08-14.
Abstract PS2-08-04: Site specific Genomic and Immune Landscapes Underpinning in metastatic Male Breast Cancer
Trapani, Dario, Deshmukh, S. Kumar, Wu, S., Xiu, Joanne , Lin, N. U., Curigliano, G., Spanheimer, P. M., Advani, P., Coelho, P. Barreto, Lustberg, M., Sledge, G. W., Tolaney, S. M., Leone, J., Lin, N. U., Curigliano, Giuseppe , Advani, P. P., Coelho, Priscila Barreto, Lustberg, Maryam , Tolaney, Sara M. , Leone, J. P.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-08-04-PS2-08-04

10.1158/1557-3265.sabcs25-ps2-08-04 Get It

Abstract Background: Male breast cancer (MaBC) is a rare malignancy, accounting for approximately 1% of all breast cancer cases. Our previous studies suggest that MaBC is biologically distinct from female breast cancer (FeBC), exhibiting a unique mutational profile and immune-genomic microenvironment. While the impact of these molecular alterations on site-specific metastases has been explored in FeBC, it remains poorly understood in MaBC. This gap limits accurate risk stratification and prediction of disease trajectory in male patients. In this study, we investigated site-specific genomic and immune alterations across metastatic sites in MaBC. Methods: 238 MaBC samples were tested by NGS (592, NextSeq; WES, NovaSeq) and WTS (NovaSeq; Caris Life Sciences, Phoenix, AZ). We performed analysis in hormone receptor-positive (HR+) and HER2-negative (HER2-) subtypes which are most common in male. HR+HER2- was defined as estrogen receptor (ER) or progesterone receptor (PR) positive and HER2 IHC 1+ or 2+ with negative chromogenic in situ hybridization (CISH) assay. Immune cells were estimated using WTS deconvolution (Quantiseq). Gene expression profiles were analyzed for T-cell inflamed score, interferon-gamma (IFN-gamma) score and MAPK Activation Score. We classified patients by site of biopsy/specimen site. Statistical significance was assessed with chi-square and Mann-Whitney U tests, p<0.05 is considered statistically significant. Results: Our cohort included 86 HR+HER2- MaBC samples biopsied from primary breast cancer (pBC) (n=39), bone (n=15), liver (n=8), lung (n=8), lymph nodes (n=7), and skin (n=9) mets. We report here only the data on statistically significant differences, but the overall landscape has been depicted across all defined-sites investigated. pBC showed a significantly lower prevalence of PIK3CA mutations (23.6% vs. 53.3%, p<0.05) compared to bone mets. ESR1 mutations were absent in pBC but present in 25% of liver and 25% of lung mets (all comparisons p<0.05). Immune profiling revealed reduced infiltration of M2 macrophages (4.3% vs. 6%, p<0.05) and neutrophil (2.2% vs. 6.9%, p<0.05) in pBC relative to bone Mets. Further, CD4+ T cells were lower in pBC compared to lymph nodes (0% vs. 2.4%, p<0.05). pBC had lower expression of immune checkpoint genes (PDCD1LG2, HAVCR2 and CD47) compared to other mets. pBC exhibited lower MAPK pathway activation score (-1.6 vs. 0.17, p=0.03) and a trend toward lower T cell-inflamed gene expression scores (-65 vs. 8, p=0.06) compared to bone mets. Bone mets had higher infiltration of M2 macrophage compared to lung (6% vs. 4.4%, p<0.05) and lymph node (6% vs. 4.5%, p<0.05). Neutrophil infiltration was elevated in bone versus liver (6.9% vs. 2%, p<0.05) but T regulatory cells were lower in bone compared to lymph nodes (1% vs. 2.4%, p<0.05). Bone showed reduced expression of CD47 (median TPM 50.6 vs. 109.9, p<0.05) compared to skin. Further bone had lower IFN-gamma scores (-0.41 vs. -0.17, p<0.05) compared to lymph node. Data on prior number and types of cancer treatment to give a context to the findings will be presented at the meeting. Conclusions: Our study highlights that each MaBC metastatic site harbors a unique genomic and immune landscape that can influence tumor behavior and potentially impact patient prognosis. Better understanding of metastatic site-specific molecular features in larger cohorts can help in the future research efforts and guiding treatment decisions. Citation Format: D. Trapani, S. Deshmukh, S. Wu, J. Xiu, N. Lin, G. Curigliano, P. Spanheimer, P. Advani, P. Barreto Coelho, M. Lustberg, G. Sledge Jr, S. Tolaney, J. Leone. Site specific Genomic and Immune Landscapes Underpinning in metastatic Male Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-08-04.
Risk Factors for Surgical Revision Following Ventricular Shunt Placement for Idiopathic Normal Pressure Hydrocephalus
Hamouda, Abdelrahman, Kumar, Rahul , Pennington, Zach, Naylor, Ryan M. , McQuinn, Michelle W., Potes, Maria Astudillo , Jusué-Torres, Ignacio, Loomis, Erica, Kim, Brian D. , Heller, Stephanie F. , Ballinger, Beth A. , Graff-Radford, Jonathan, Jones, D. Richard, Cutsforth-Gregory, Jeremy K., Cogswell, Petrice M., Rinaldo, Lorenzo , Meyer, Frederic B., Elder, Benjamin D., Pennington, Zach , Astudillo Potes, Maria D, Loomis, Erica A, Pennington, Zach , Kumar, Rahul , Hamouda, Abdelrahman M. , Jusué-Torres, Ignacio , Graff‐Radford, Jonathan , Jones, David T. , Cutsforth‐Gregory, Jeremy K. , Cogswell, Petrice M. , Elder, Benjamin D.

Mayo Clinic

Operative Neurosurgery | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000001964 | PMID 41705955 Get It

BACKGROUND AND OBJECTIVES: Ventriculoperitoneal shunt (VPS) placement is a common treatment for idiopathic normal pressure hydrocephalus (iNPH), but patients may require VPS revision. This study aims to evaluate the effectiveness of a standardized VPS placement protocol by comparing indications and rates of shunt revision compared with a historical institutional cohort. METHODS: All patients treated with VPS for “suspected” iNPH at a tertiary care center between January 2000 and January 2023 were retrospectively reviewed and divided into temporally distinct historical (before 2017) and standardized (after 2017) cohorts. Cumulative incidence and timing of VPS revision were compared using competing risks analyses. RESULTS: A total of 561 patients (median age 75.0 years) were identified with 324 (57.8%) in the historical and 237 (42.2%) in the standardized cohorts. Significant variations in surgical technique and shunt hardware were noted between the cohorts. With a median follow-up of 11.4 months for historical and 12.4 months for standardized cohort, shunt revisions occurred in 19.4% and 8.4% of patients in the historical and standardized cohorts, respectively ( P < .001). Revision indications also varied significantly with lower rates of overdrainage ( P < .001), infection ( P < .001), and proximal malfunction ( P = .042) but higher rate of distal malfunction ( P = .03) in the standardized cohort. Notably, no infections were noted in the standardized cohort. CONCLUSION: Risk of shunt revision among iNPH patients may be associated with modifiable factors related to surgical technique and shunt hardware selection. Importantly, no short-term complications such as hemorrhage, infection, or catheter malposition were observed with the standardized protocol. Development and refinement of standardized shunt protocols for iNPH patients should be commonplace to facilitate tracking, identification, and modification of modifiable technical risk factors.
Response Assessment in Pediatric Neuro-Oncology Symposium, Pediatric Society of Neuro-Oncology proceedings: Current status and future initiatives
Fangusaro, Jason, Warren, Katherine, Hargrave, Darren, Gampel, Bradley , Baxter, Patricia A, Perreault, Sébastien , Vézina, Gilbert , Mueller, Sabine, Kram, David E, Erker, Craig, Stuckert, Austin J. , Kazerooni, Anahita Fathi, Mahdi, Jasia , Leary, Sarah, Susan, N., Prados, Michael, Mankad, Kshitij, Salloum, Ralph , Reddy, A. O., Dhall, Girish, Lai, Holly, Rameh, Vanessa , Jaju, Alok , Laughlin, Suzanne , Green, Adam L. , Hwang, Eugene I., Silvera, V Michelle, Ho, Chang Y, Nabavizadeh, Ali, Kline, Cassie , Raju, Praveen, Shivaram, Avula, Kann, Benjamin H, Mirsky, Prof David M, Fangusaro, Jason , Warren, Katherine N, Hargrave, Darren R. , Robinson, Giles , Baxter, Patricia Ann , Mueller, Sabine , Takami, Hirokazu , Kram, David E. , Erker, Craig , Foreman, Nicholas K. , Kazerooni, Anahita Fathi , Leary, Sarah , Chi, Susan N , Prados, Michael D. , Tamrazi, Benita , Mankad, Kshitij , Gonçalves, Fabrício Guimarães , Hansford, Jordan R. , Reddy, Alyssa , Bhatia, Aashim , Bag, Asim Kumar , Wright, Jason N. , Bartels, Ute , Kilburn, Lindsay Baker , Robison, Nathan John , Mangum, Ross , Yeo, Kee Kiat , Lassaletta, Álvaro , Ho, Chang Yueh , Nabavizadeh, Ali , Margol, Ashley , Cohen, Kenneth J. , Avula, Shivaram , Kann, Benjamin H.

Mayo Clinic

Neuro-Oncology Pediatrics | February 18, 2026 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/neuped/wuag010 Get It

Abstract Response Assessment in Pediatric Neuro-Oncology (RAPNO) is an international working group dedicated to developing standardized recommendations for response assessment in children with central nervous system tumors enrolled on clinical trials. This standardization facilitates easier and more reliable comparison of responses across trials. Since the first RAPNO publication in 2013, response guidelines have been issued for medulloblastoma (MB), low-grade glioma (LGG), high-grade glioma (HGG), diffuse intrinsic pontine glioma, ependymoma, and craniopharyngioma. Many of these guidelines have already been incorporated into clinical trials to evaluate their effectiveness and accuracy. RAPNO has always been predicated on the idea that these consensus recommendations will require updates over time as they are applied in practice given technological advancements, evolving treatment approaches, and growing knowledge of disease pathology. A half-day RAPNO symposium sponsored by the Society of Neuro-Oncology was held in San Diego, California, United States, on May 15, 2025. This event coincided with the 8th Biennial Pediatric Society of Neuro-Oncology meeting. The main objectives were to identify ongoing RAPNO challenges, discuss potential updates, and plan future initiatives across 3 specific groups: (1) LGG/Craniopharyngioma, (2) HGG/diffuse midline glioma (DMG)/Ependymoma, and (3) MB and other seeding tumors. This manuscript reviews the symposium proceedings and highlights key topics and challenges discussed, as well as outlining future RAPNO initiatives.
A Framework and Method for Measuring the Implementation of Data Science in Critical Care
Woznica, Daniel M., Al-Hakim, Tamara, Kumar, Vishakha K. , Cobb, J. Perren, Khanna, Ashish K., Reuter-Rice, Karin, Laudański, Krzysztof , Al-Hakim, Tamara, Cobb, J. Perren, Kamaleswaran, Rishikesan , Khanna, Ashish K. , Zimmerman, Jerry J. , Reuter‐Rice, Karin

Mayo Clinic

Critical Care Explorations | February 17, 2026 | Volume: 8 | Issue: 2 | Pages: e1372

10.1097/cce.0000000000001372 | PMID 41701949 Get It

BACKGROUND: The implementation of data science concepts, skills, and tools in critical care research and practice faces multiple, complex barriers. METHODS: We developed an implementation science-based framework and method for measuring the adoption, implementation, and sustainment of data science concepts, skills, and tools in critical care—the Society of Critical Care Medicine (SCCM) Discovery Data Science Campaign (DSC) Implementation Research Logic Model (IRLM). Our IRLM specifies constructs for: 1) key determinants (i.e., barriers and facilitators) influencing the implementation of data science concepts, skills, and tools in critical care; 2) implementation strategies deployed by the SCCM Discovery DSC to address these determinants; 3) theorized mechanisms of action by which these strategies affect outcomes; and 4) upstream and downstream implementation outcomes influenced by implementation strategies. RESULTS AND CONCLUSIONS: We believe that our model can facilitate more rigorous measurement of theoretically grounded, empirically assessable factors driving implementation of data science concepts, skills, and tools in critical care.